Abstract: The position detection apparatus is provided comprising: an acquisition section that acquires a magnetic field pattern from a detection target apparatus comprising a detection unit having a plurality of magnetic sensor sections and a moving unit configured to provide the magnetic field pattern corresponding to the position with respect to the detection unit to the plurality of magnetic sensor sections; a reference pattern output section that outputs reference patterns respectively corresponding to each of a plurality of candidate positions of the moving unit with respect to the detection unit; and a detection section that detects which of the plurality of candidate positions is a position of the moving unit with respect to the detection unit based on a result of comparison of the acquired magnetic field pattern and the reference pattern corresponding to each of the plurality of candidate positions.

Abstract: Provided is a drive apparatus including: a first drive unit group including first drive units, each for generating a magnetic field to drive a first object provided with a first lens and magnet in an optical axis direction; and a second drive unit group including second drive units, each for generating a magnetic field to drive a second object provided with a second lens and magnet in the direction. Each of the first and second drive units includes a first and second terminal connected via a clock and data signal line to a master controlling the drive unit as a slave. In at least one of the first drive units, the first and second terminals are respectively forward-connected to the clock and data signal lines. In at least one of the second drive units, the second and first terminals are respectively reverse-connected to the clock and data signal lines.

Abstract: Provided is a calibration apparatus comprising: a driving control unit to drive an object provided with a lens in a movable range for moving the object in an optical axis-direction by sequentially controlling a plurality of drive units configured to drive the object within each of a plurality of sections into which the movable range is divided, in calibration of a drive apparatus including: the plurality of drive units; and a magnetic field detection unit configured to detect a magnetic field corresponding to a position of the object; a position acquisition unit to acquire position data of the object; a magnetic field acquisition unit to acquire magnetic field data corresponding to a position of the object; and a generating unit to generate, based on the position data and the magnetic field data, end point information to determine a driving range in each of the plurality of sections.

Abstract: The position detection apparatus is provided comprising: an acquisition section that acquires a magnetic field pattern from a detection target apparatus comprising a detection unit having a plurality of magnetic sensor sections and a moving unit configured to provide the magnetic field pattern corresponding to the position with respect to the detection unit to the plurality of magnetic sensor sections; a reference pattern output section that outputs reference patterns respectively corresponding to each of a plurality of candidate positions of the moving unit with respect to the detection unit; and a detection section that detects which of the plurality of candidate positions is a position of the moving unit with respect to the detection unit based on a result of comparison of the acquired magnetic field pattern and the reference pattern corresponding to each of the plurality of candidate positions.

Abstract: The present invention mainly aims to provide a drug for the prophylaxis or treatment of androgen-independent prostate cancer, which is highly useful as a pharmaceutical agent. The present invention provides a drug for the prophylaxis or treatment of androgen-independent prostate cancer, containing a steroid C17,20 lyase inhibitor, particularly, a compound represented by the formula (I): wherein n is an integer of 1 to 3, and Ar is an aromatic ring optionally having substituent(s), or a salt thereof or a prodrug thereof.

Abstract: A combination agent containing an LHRH receptor agonist or antagonist and an androgen receptor agonist, which is useful as an agent for the prophylaxis or treatment of hormone-dependent diseases and the like, is provided.

Abstract: The present invention mainly aims to provide a drug for the prophylaxis or treatment of androgen-independent prostate cancer, which is highly useful as a pharmaceutical agent. The present invention provides a drug for the prophylaxis or treatment of androgen-independent prostate cancer, containing a steroid C17,20 lyase inhibitor, particularly, a compound represented by the formula (I): wherein n is an integer of 1 to 3, and Ar is an aromatic ring optionally having substituent(s), or a salt thereof or a prodrug thereof.

Abstract: It is intended to provide a screening method of a compound having an effect of inhibiting the production of a prostatic specific antigen and/or an effect of suppressing the proliferation of androgen-independent prostatic cancer, comprising using an androgen-independent human prostatic cancer cell.

Abstract: The present invention provides a compound represented by the general formula: [wherein Ring A represents an optionally substituted 5- to 8-membered ring, Ring B represents a further optionally substituted 4- to 10-membered ring, Ring C represents a further optionally substituted benzene ring, X1 represents carbon atom, X2 represents a carbon atom, an oxygen atom, etc., W represents a nitrogen atom, etc., Y11 represents a group represented by the formula CR2R3? (wherein R2 represents a hydrogen atom, a cyano group, a nitro group, etc., and R3? represents a hydrogen atom, a cyano group, a nitro group, etc., respectively), Y21 represents a group represented by the formula CR4R5? (wherein R4 represents a hydrogen atom, a cyano group, a nitro group, etc., and R5? represents a hydrogen atom, a cyano group, a nitro group, etc., respectively), etc., and R1 represents an electron-withdrawing group, respectively.

Abstract: This invention provides a semiconductor memory device and its data writing method capable of saving the needed time to a minimum even in repeating a data write operation maximum number of times. More specifically, this invention provides a semiconductor memory device and its data writing method as follows. A flash memory 101 is set at a test mode by fixing the test pad TP at L level. When a verify operation passes, a verify pass signal input terminal (VPASS) of a data write controlling circuit WCC and a verify pass signal input terminal (VPASS) of a data write counter circuit WCT are fixed at L level by a verify pass signal invalidating means 3 although a verify circuit VC outputs an L level verify pass signal VPASS. A latch circuit LC holds a latched verify pass signal VPL at H level and a verify start signal input terminal (VR) of the verify circuit VC is fixed at L level. A write operation without a verify operation is repeated number of times preset in the data write counter circuit WCT.

Abstract: A tissue-selective androgen receptor modulator containing a compound represented by the formula wherein Ring A represents an optionally substituted 5- to 8-membered ring, Ring B represents an optionally further substituted 4- to 10-membered ring, Ring C represents an optionally further substituted benzene ring, X1 represents an optionally substituted carbon atom, X2 represents an optionally substituted carbon atom, an oxygen atom and the like, W1 represents a nitrogen atom and the like, Y11 represents a group represented by the formula CR2R3? (wherein R2 represents a hydrogen atom, a cyano group, a nitro group and the like, and R3? represents a bond, a hydrogen atom, a cyano group, a nitro group and the like, respectively), Y21 represents a group represented by the formula CR4R5? (wherein R4 represents a hydrogen atom, a cyano group, a nitro group and the like, and R5? represents a bond, a hydrogen atom, a cyano group, a nitro group and the like, respectively) and the like, R1 represents an electron-withd

Abstract: A combination agent containing an LHRH receptor agonist or antagonist and an androgen receptor agonist, which is useful as an agent for the prophylaxis or treatment of hormone-dependent diseases and the like, is provided.

Abstract: The present invention provides a compound represented by the general formula: [wherein Ring A represents an optionally substituted 5- to 8-membered ring, Ring B represents a further optionally substituted 4- to 10-membered ring, Ring C represents a further optionally substituted benzene ring, X1 represents carbon atom, X2 represents a carbon atom, an oxygen atom, etc., W represents a nitrogen atom, etc., Y11 represents a group represented by the formula CR2R3? (wherein R2 represents a hydrogen atom, a cyano group, a nitro group, etc., and R3? represents a hydrogen atom, a cyano group, a nitro group, etc., respectively), Y21 represents a group represented by the formula CR4R5? (wherein R4 represents a hydrogen atom, a cyano group, a nitro group, etc., and R5? represents a hydrogen atom, a cyano group, a nitro group, etc., respectively), etc., and R1 represents an electron-withdrawing group, respectively.

Abstract: The present invention provides a mutant androgen receptor (AR) useful for screening an agent for the prophylaxis/treatment of androgen-independent cancer and the like, DNA encoding the AR and the like. It also provides a method of producing a mutant AR expressing cancer cell line in vitro, a method of screening for an anti-antiandrogen drug using the mutant AR expressing cancer cell line obtained by this method, a method of classifying anti-androgen drugs, a cocktail therapy agent comprising a combination of anti-androgen drugs classified by this method and the like.

Abstract: A combination agent containing an LHRH receptor agonist or antagonist and an androgen receptor agonist, which is useful as an agent for the prophylaxis or treatment of hormone-dependent diseases and the like, is provided.

Abstract: The present invention provides an androgen receptor antagonistic agent and a superior prophylactic or therapeutic agent for hormone-sensitive cancer, which contain a compound of the formula: wherein, R1 is a hydrogen atom, a group binding through a carbon atom, a group binding through a nitrogen atom, a group binding through an oxygen atom or a group binding through a sulfur atom, R2 is a hydrogen atom, a group binding through a carbon atom, a group binding through a nitrogen atom, a group binding through an oxygen atom or a group binding through a sulfur atom, R3 is a hydrogen atom, a hydrocarbon group which may have substituent(s), an acyl group or a heterocyclic group which may have substituent(s), R4 is a hydrogen atom, a group binding through a carbon atom, a group binding through a nitrogen atom, a group binding through an oxygen atom or a group binding through a sulfur atom, and R5 is a cyclic group which may have substituent(s); or a salt thereof, or its prodrug.

Abstract: This invention provides a semiconductor memory device and its data writing method capable of saving the needed time to a minimum even in repeating a data write operation maximum number of times. More specifically, this invention provides a semiconductor memory device and its data writing method as follows. A flash memory 101 is set at a test mode by fixing the test pad TP at L level. When a verify operation passes, a verify pass signal input terminal (VPASS) of a data write controlling circuit WCC and a verify pass signal input terminal (VPASS) of a data write counter circuit WCT are fixed at L level by a verify pass signal invalidating means 3 although a verify circuit VC outputs an L level verify pass signal VPASS. A latch circuit LC holds a latched verify pass signal VPL at H level and a verify start signal input terminal (VR) of the verify circuit VC is fixed at L level. A write operation without a verify operation is repeated number of times preset in the data write counter circuit WCT.